Join

Compare · BNTX vs IMRA

BNTX vs IMRA

Side-by-side comparison of BioNTech SE (BNTX) and IMARA Inc. (IMRA): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both BNTX and IMRA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
  • BNTX is the larger of the two at $24.78B, about 683.5x IMRA ($36.3M).
  • Over the past year, BNTX is down 3.3% and IMRA is down 59.2% - BNTX leads by 55.9 points.
  • BNTX has hit the wire 8 times in the past 4 weeks while IMRA has been quiet.
  • BNTX has more recent analyst coverage (25 ratings vs 3 for IMRA).
PerformanceBNTX-5.29%IMRA-59.18%
2025-10-15+0.00%2026-09-08
MetricBNTXIMRA
Company
BioNTech SE
IMARA Inc.
Price
$98.75-4.81%
$14.58-4.08%
Market cap
$24.78B
$36.3M
1M return
+5.42%
-12.59%
1Y return
-3.28%
-59.18%
Sector
Health Care
Health Care
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NASDAQ
NASDAQ
IPO
2019
2020
News (4w)
8
0
Recent ratings
25
3
BNTX

BioNTech SE

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

IMRA

IMARA Inc.

IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. It develops IMR-687, an oral, once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Latest BNTX

Latest IMRA